Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study
Authors' conclusion
In adults with Type 1 diabetes and obesity, semaglutide discontinuation was associated with a greater decline in time in range and increased glycaemic variability compared with placebo over 12 weeks.
Study context
- Population
- Adults with T1D and obesity using AID who completed the ADJUST-T1D RCT
- Participants
- 16 vs 22
- Comparison
- Semaglutide discontinuation vs placebo
- Semaglutiden = 16
- Placebon = 22reference
- Primary endpoint
- Change in TIR (70-180 mg/dL) and other CGM metrics from Week 26 to the extension phase
- Follow-up
- 12 weeks
Methodological details12-week extension phase, Wilcoxon rank-sum tests with Benjamini-Hochberg adjustment, analysis of covariance (ANCOVA) sensitivity analysis
- 12-week extension phase
- Wilcoxon rank-sum tests with Benjamini-Hochberg adjustment
- ANCOVA sensitivity analysis
Primary result
As reported in the abstract
Change in TIR (70-180 mg/dL) · Week 26 to 12-week extension
Semaglutide
−3.6
median · %
Placebo
1.5
median · %
Adjusted p = 0.044
Further findings
Increase in glucose SD
adjusted p = 0.044
Increase in CV
adjusted p = 0.044
- TAR (> 180 mg/dL)
- adjusted p = 0.064
TAR (> 180 mg/dL)
- Increased numerically but did not remain significant after adjustment
Hypoglycaemia-related continuous glucose monitoring (CGM) metrics
- No significant between-group differences
ANCOVA sensitivity analysis
- ANCOVA analyses showed consistent findings
Original publication
Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study. Diabetes Obes Metab. Published 31 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →